Clinical Trial

Study for AZD4360 in Participants With Advanced Solid Tumours

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD4360 in adult participants with locally advanced or metastatic solid tumours selected for expression of CLDN18.2.
Protocol Amendment History 3 changes
critical Enrollment closed, study ongoing 2026-08-01
notable Enrollment reduced: 117 -> 31 participants 2026-08-01
notable Trial sites reduced: 18 -> 14 locations 2026-08-01
Trial Details
NCT Number NCT06921928
Lead Sponsor AstraZeneca
Conditions Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
Enrollment 31 participants
Start Date 2025-04-29
Primary Completion 2027-03-31 (estimated)
Study Completion 2027-12-16 (estimated)
Updated on ClinicalTrials.gov 2026-07-31